MedElevator
Войти в исследования International journal of antimicrobial agents · 2026
Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacterales bacteraemia in high-risk neutropenic patients in haematology: A multicentre retrospective study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lars William, Gaborit Benjamin, Coste Anne, Le Bourgeois Amandine, Marchand Tony, Guillerm Gaëlle, Guillouzouic Aurélie, Turban Adrien, Lamoureux Claudie, Rezig Schéhérazade, Boutoille David, Revest Matthieu, Ansart Séverine, Talarmin Jean-Philippe, Paret Raphaël
Аннотация
OBJECTIVE: Extended-spectrum β-lactamase-producing Enterobacterales (ESBL-EB) infections are associated with poor outcomes in febrile neutropenia. The early identification of patients at risk during prolonged chemotherapy-induced neutropenia remains challenging.
METHODS: This multicentre retrospective cohort study included patients with a first Enterobacterales bacteraemia during neutropenia following induction, consolidation, or stem cell transplantation (2015-2022). ESBL-EB bacteraemia was compared with non-ESBL-EB bacteraemia using multivariable logistic regression. Secondary analysis assessed the association between specific antibiotic classes and ESBL-EB, and the impact of prior antibiotic exposure on phenotypic β-lactam resistance profiles.
RESULTS: Amongst 574 patients with Enterobacterales bacteraemia, 74 (12.9%) had ESBL-EB bacteraemia. The mean neutropenia duration was 15.8 ± 10.4 d. Inappropriate empirical therapy (73% vs. 10%, P < 0.001) was more frequent in ESBL-EB bacteraemia. In multivariable analysis, antibiotic exposure within 30 d (aOR 2.46, 95% confidence interval [CI] 1.38-4.38, P = 0.002) and mucosal lesions (aOR 3.20, 95% CI 1.58-7.23, P = 0.002) were associated with ESBL-EB bacteraemia. Prior cefepime exposure (adjusted odds ratio [aOR] 2.91, 95% CI 1.07-8.34; P = 0.04) and exposure to multiple antibiotics (aOR 2.88, 95% CI 1.09-7.99; P = 0.03) were associated with ESBL-EB bacteraemia compared with piperacillin-tazobactam exposure. Cefepime exposure was associated with a higher proportion of ESBL-producing isolates (37.2% vs. 18.6%, P = 0.04), whereas piperacillin-tazobactam exposure was associated with high-level penicillinase producers (37.3% vs. 2.3%, P < 0.001).
CONCLUSIONS: Recent antibiotic exposure and mucosal lesions are independent risk factors for ESBL-EB bacteraemia in high-risk neutropenic patients. Prior cefepime exposure was associated with ESBL-EB bacteraemia in comparison with piperacillin-tazobactam exposure; this exploratory finding requires confirmation in prospective studies.
METHODS: This multicentre retrospective cohort study included patients with a first Enterobacterales bacteraemia during neutropenia following induction, consolidation, or stem cell transplantation (2015-2022). ESBL-EB bacteraemia was compared with non-ESBL-EB bacteraemia using multivariable logistic regression. Secondary analysis assessed the association between specific antibiotic classes and ESBL-EB, and the impact of prior antibiotic exposure on phenotypic β-lactam resistance profiles.
RESULTS: Amongst 574 patients with Enterobacterales bacteraemia, 74 (12.9%) had ESBL-EB bacteraemia. The mean neutropenia duration was 15.8 ± 10.4 d. Inappropriate empirical therapy (73% vs. 10%, P < 0.001) was more frequent in ESBL-EB bacteraemia. In multivariable analysis, antibiotic exposure within 30 d (aOR 2.46, 95% confidence interval [CI] 1.38-4.38, P = 0.002) and mucosal lesions (aOR 3.20, 95% CI 1.58-7.23, P = 0.002) were associated with ESBL-EB bacteraemia. Prior cefepime exposure (adjusted odds ratio [aOR] 2.91, 95% CI 1.07-8.34; P = 0.04) and exposure to multiple antibiotics (aOR 2.88, 95% CI 1.09-7.99; P = 0.03) were associated with ESBL-EB bacteraemia compared with piperacillin-tazobactam exposure. Cefepime exposure was associated with a higher proportion of ESBL-producing isolates (37.2% vs. 18.6%, P = 0.04), whereas piperacillin-tazobactam exposure was associated with high-level penicillinase producers (37.3% vs. 2.3%, P < 0.001).
CONCLUSIONS: Recent antibiotic exposure and mucosal lesions are independent risk factors for ESBL-EB bacteraemia in high-risk neutropenic patients. Prior cefepime exposure was associated with ESBL-EB bacteraemia in comparison with piperacillin-tazobactam exposure; this exploratory finding requires confirmation in prospective studies.